Latest news with #Embase
Medscape
2 days ago
- Health
- Medscape
NIPPV Outperforms NCPAP in Premature Infant Lung Care
TOPLINE: Nasal intermittent positive pressure ventilation (NIPPV) reduced the risk of requiring invasive ventilation and developing bronchopulmonary dysplasia by nearly half compared with nasal continuous positive airway pressure (NCPAP) in premature infants with respiratory distress syndrome. METHODOLOGY: Researchers conducted an updated meta-analysis of 14 randomized trials involving 1755 premature infants (< 37 weeks' gestation) with respiratory distress syndrome to compare NIPPV with NCPAP as their initial respiratory support. Data were gathered through systematic searches of Medline, Embase, Web of Science, and the Cochrane Central Register of Controlled Trials for studies published between 1980 and February 2022. Primary outcomes were the incidence of invasive ventilation and bronchopulmonary dysplasia. Subgroup analyses were stratified by — infants who received surfactant treatment, gestational age (> 30 or ≤ 30 weeks), and birth weight (> or ≤ 1500 g). Secondary outcomes included mortality, pulmonary air leaks, retinopathy of prematurity stage ≥ 2, necrotizing enterocolitis Bell stage ≥ 2, and intraventricular hemorrhage grade ≥ 3. TAKEAWAY: NIPPV demonstrated superior efficacy with a 47% reduction in the incidence of invasive ventilation requirement (relative risk [RR], 0.53; P < .001) and a 49% reduction in the incidence of bronchopulmonary dysplasia (RR, 0.48; P = .004) compared with NCPAP. Benefits of NIPPV on invasive ventilation incidence persisted across subgroups defined by gestational age, birth weight, and surfactant treatment. However, reductions in bronchopulmonary dysplasia were significant only when stratified by gestational age. Secondary outcomes showed no significant differences between groups. No increase in pneumothorax was observed with NIPPV. IN PRACTICE: 'While these findings are promising, higher-quality randomized controlled trials with standardized protocols are needed before definitive clinical recommendations can be established,' the authors of the study wrote. SOURCE: This study was led by Juan Zeng, Southwest Hospital of Army Medical University, and Rong Tan, Jiulongpo People's Hospital, both in Chongqing, China. It was published online on June 28, 2025, in the European Journal of Pediatrics. LIMITATIONS: Although synchronized NIPPV may offer advantages over nonsynchronized NIPPV, insufficient data prevented subgroup comparisons of the two modes. As most trials enrolled infants with gestational age > 30 weeks, the findings may not be generalizable to extremely premature neonates. Finally, the overall low methodological quality and limited number of robust, high-quality studies reduce confidence in these conclusions. DISCLOSURES: The authors declared that they did not receive any funds, grants, or other support. The authors declared having no conflicts of interest. This article was created using several editorial tools, including AI, as part of the process. Human editors reviewed this content before publication.
Techday NZ
26-06-2025
- Health
- Techday NZ
Elsevier unveils Embase AI to transform biomedical data research
Elsevier has launched Embase AI, a generative artificial intelligence tool aimed at changing how researchers and medical professionals access and analyse biomedical data. The tool has been developed in collaboration with the scientific community and is built upon Elsevier's Embase platform, a widely used biomedical literature database. According to feedback from beta users, Embase AI can reduce the time spent on reviewing biomedical data by as much as 50%. Natural language features Among its central features, Embase AI allows users to conduct searches in natural language, ranging from basic to complex scientific queries. The system then provides instant summaries of the relevant data and research insights. Each answer comes with a list of linked citations to assist users in evaluating the evidence and meeting expectations around medical regulation. Unlike some other AI solutions that may obscure data provenance, Embase AI delivers transparency by presenting citations and ensuring that the underlying sources can be cross-checked. The database underpinning Embase AI is updated continuously and includes records such as adverse drug reaction reports, peer-reviewed journal articles, and around 500,000 clinical trial listings from This makes it suitable for a range of professional needs, including medical research, pharmacovigilance, regulatory submissions and the generation of market insights. Expanded access By enabling natural language querying, Embase AI seeks to open up biomedical data analysis to a broader group of users, including those who may lack advanced technical experience with literature reviews. Information is summarised for swift consumption while retaining the supporting references, limiting the likelihood that important findings go overlooked. The AI solution uses a dual-stage ranking system to generate summary responses with inline citations. This approach is designed to ensure transparency and help users trust the results. A human-curated hierarchy of medical concepts and their synonyms underpins the system, contributing to the precision and transparency of its outputs. Embase AI's records are updated daily, and its architecture allows the tool to function in real time, searching the platform's full content including peer-reviewed research, clinical trials, preprints and conference abstracts. Security and privacy Elsevier has stated that Embase AI was developed in accordance with its Responsible AI Principles and Privacy Principles to ensure robust data privacy and security. The company notes that the model's use of third-party large language models (LLMs) is private, with no user information being stored or employed to train public versions of these models. All data is retained solely within Elsevier's protected environment. "Embase AI is changing the way researchers and other users go about solving problems and helps them save valuable time searching for answers, digesting information, and avoiding the risk of missing valuable insights. Every user should have access to trusted research tools that help them advance human progress, and we remain committed to working in partnership with scientists across academia, life sciences and other innovative industries to ensure that our solutions address their needs. We know that our users seek solutions that they can trust, and we built Embase AI in a way that ensures transparency, explainability and accuracy." This statement was made by Mirit Eldor, Managing Director, Life Sciences at Elsevier. Ongoing development Embase AI is the latest addition to Elsevier's suite of products aimed at supporting the biomedical research community by facilitating discovery, analysis, and evidence synthesis using responsibly developed AI tools underpinned by trusted content. The platform is designed to meet the needs of professionals in roles such as research and development, medical affairs, academic research, knowledge management, and medical education.
Medscape
07-05-2025
- Health
- Medscape
Which Treatments Lead Neuropathic Pain Care?
A meta-analysis of 313 trials found that tricyclic antidepressants (TCAs), serotonin and norepinephrine reuptake inhibitors (SNRIs), and alpha-2-delta ligands offered modest efficacy for neuropathic pain and were recommended as first-line treatments. Capsaicin 8% patches, capsaicin cream, and lidocaine 5% plasters were recommended as second-line treatments, and botulinum toxin type A, repetitive transcranial magnetic stimulation (rTMS), and opioids were recommended as third-line treatments. METHODOLOGY: Researchers conducted systematic searches in Embase, PubMed, the International Clinical Trials Registry, and A total of 313 trials (284 pharmacologic and 29 neuromodulation studies) were analysed, comprising 48,789 adults treated for neuropathic pain. The primary efficacy outcome was the proportion of participants achieving at least 50% or 30% reduction in baseline pain intensity or moderate pain relief, and the primary safety outcome was the number of participants who withdrew from treatment due to adverse events. Nine neuromodulation and 89 pharmacologic interventions were assessed. For each treatment, risk differences were used to determine the number needed to treat (NNT) and the number needed to harm (NNH). TAKEAWAY: Strong recommendations were made for the use of TCAs (NNT, 4.6; NNH, 17.1; moderate certainty of evidence), alpha-2-delta ligands (NNT, 8.9; NNH, 26.2; moderate certainty of evidence), and SNRIs (NNT, 7.4; NNH, 13.9; moderate certainty of evidence) as first-line treatments. Weak recommendations were made for the use of capsaicin 8% patches (NNT, 13.2; NNH, 1129.3; moderate certainty of evidence), capsaicin cream (NNT, 6.1; NNH, 18.6; very low certainty of evidence), and lidocaine 5% plasters (NNT, 14.5; NNH, 178.0; very low certainty of evidence) as second-line treatments. Furthermore, weak recommendations were made for the use of botulinum toxin type A (NNT, 2.7; NNH, 216.3; moderate certainty of evidence), rTMS (NNT, 4.2; NNH, 651.6; low certainty of evidence), and opioids (NNT, 5.9; NNH, 15.4; low certainty of evidence) as third-line treatments. IN PRACTICE: "The recommendations highlight the need for shared decision making, prioritising patient autonomy and preferences when tailoring treatment strategies. Health-care professionals should adapt these guidelines to their specific contexts, accounting for the cost, accessibility, and feasibility of treatments," the authors wrote, emphasizing the need for further "placebo-controlled or sham-controlled trials done over clinically relevant timeframes." SOURCE: This study was led by Nadia Soliman, PhD, Imperial College London, London, England, and Xavier Moisset, MD, Université Clermont Auvergne, CHU Clermont-Ferrand, Clermont-Ferrand, France. It was published online in the May 2025 issue of The Lancet Neurology . LIMITATIONS: This study was limited by potentially selective decision-making and heterogeneity in trial design, outcome measures, and reporting, thereby reducing precision. Crossover designs and inconsistent placebo responses may have contributed to changes in treatment effect estimates. Several studies lacked dose-response data, detailed adverse event reporting, and long-term follow-up, constraining safety assessments. DISCLOSURES: This study was funded by the NeuPSIG committee and ERA-NET Neuron. Several authors reported having various ties with various sources. Details are provided in the original article.
Yahoo
06-05-2025
- Health
- Yahoo
Elsevier adds half a million records from ClinicalTrials.gov to Embase, enabling a seamless search experience in the world's most comprehensive biomedical database
Data from studies conducted in more than 200 countries supports greater access to research and facilitates systematic reviews, clinical trial design, medical device approvals and improved drug safety LONDON, May 6, 2025 /PRNewswire/ -- Elsevier, a global leader in information and analytics, is announcing the addition of half a million records from to its leading biomedical literature database, Embase. The integration will enable researchers to seamlessly view high-quality information on clinical research studies and their results alongside the peer-reviewed literature, in-press publications and conference abstracts already available in Embase. Researchers will be able to conduct more comprehensive evidence and literature searches while having the confidence they will never miss important updates relevant to their drug, therapy, or medical device. Clinical trials data is a vital component of biomedical literature search, helping pharmaceutical and medical device companies stay informed about the latest scientific advancements, regulatory requirements, and competitive insights to support evidence-based decision-making. However, gathering data from multiple sources is currently prone to errors and is time-consuming, such as the duplication of search results, which slows research and regulatory processes. As new therapies and devices are developed and R&D organizations seek collaborative partners, they must undertake thorough searches and justifications of evidence. This process becomes challenging when data must be sourced from differing platforms, and regulatory and compliance requirements continue to evolve. The addition of data to Embase will improve researcher workflows by making clinical data searchable within Embase's user-friendly interface. By presenting all biomedical evidence in a single platform, Embase enables researchers to better align and analyze search results, as well as export data into a citation manager. Clinical trials will be automatically indexed using the latest Emtree vocabulary, ensuring they are indexed accurately based on their title, a brief summary and detailed description. This new integration continues to support multiple use cases that Embase delivers to users, including to medical affairs, to understand clinical endpoints, outcomes and patient populations for already-approved drugs, providing competitive intelligence, supporting medical device development and approval, improving clinical trial design, and improving drug safety. By late 2025, Embase will further expand its coverage to include eligibility criteria and study plan information, reinforcing its role as a comprehensive platform for accessing both published literature and clinical trial registry data. Mirit Eldor, Managing Director of the Life Sciences business at Elsevier, said, "Researchers are under increasing pressure to conduct comprehensive evidence searches with accuracy and efficiency, ensuring no critical information is overlooked. The incorporation of clinical trials data into Embase is the latest example of Elsevier's commitment to developing innovative solutions that enhance researchers' workflows. With access to comprehensive, high-quality data, researchers can reduce time spent on manual searches, while making more informed decisions that ensure the integrity of their company's drug, therapy, or medical device. We have had many requests from customers to add Clinical Trials data into Embase and I'm delighted that we are able to improve the value that we deliver to our customers" About Elsevier A global leader in advanced information and decision support, Elsevier helps to advance science and healthcare, to advance human progress. We do this by facilitating insights and critical decision-making with innovative solutions based on trusted, evidence-based content and advanced AI-enabled digital technologies. We have supported the work of our research and healthcare communities for more than 140 years. Our 9,700 employees around the world, including 2,300 technologists, are dedicated to supporting researchers, librarians, academic leaders, funders, governments, R&D-intensive companies, doctors, nurses, future healthcare professionals and educators in their critical work. Our 3,000 scientific journals and iconic reference books include the foremost titles in their fields, including Cell Press, The Lancet and Gray's Anatomy. Together with the Elsevier Foundation, we work in partnership with the communities we serve to advance inclusion in science, research and healthcare in developing countries and around the world. Elsevier is part of RELX, a global provider of information-based analytics and decision tools for professional and business customers. For more information on our work, digital solutions and content, visit Logo - View original content to download multimedia: SOURCE Elsevier Limited Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
